First Patient Enrolled in Phase 4 Trial of Wize Pharma’s Dry Eye Treatment for Sjogren’s
Wize Pharma has enrolled the first participant in a Phase 4 clinical trial investigating the company’s LO2A drops to prevent the dry eye seen in Sjogren’s syndrome. The trial (NCT03319420) in Israel will compare LO2A’s ability to relieve dry eyes with that of an over-the-counter treatment known as Systane…